Abstract
Ferritinophagy is a type of autophagy mediated by nuclear receptor activator 4 (NCOA4), which plays a role in inducing ferroptosis by regulating iron homeostasis and producing reactive oxygen species in cells. Under physiological conditions, ferritinophagy maintains the stability of intracellular iron by regulating the release of free iron. Studies have demonstrated that ferritinophagy is necessary to induce ferroptosis; however, under pathological conditions, excessive ferritinophagy results in the release of free iron in large quantities, which leads to lipid peroxidation and iron-dependent cell death, known as ferroptosis. Ferritinophagy has become an area of interest in recent years. We here in review the mechanism of ferritinophagy and its association with ferroptosis and various diseases to provide a reference for future clinical and scientific studies.
Introduction
Ferroptosis is an iron-dependent, non-apoptotic mechanism of cell death, and the production of reactive oxygen species (ROS) and lipid peroxidation leading to plasma membrane damage are the core events leading to ferroptosis. The main marker of ferroptosis is phospholipid hydroperoxides (PLOOHs), which is composed of phospholipids containing polyunsaturated fatty acids (PUFAs) in cell membranes (PUFA-PLs) (). Lipidomics studies have shown that phosphatidylethanolamine is more strongly associated with ferroptosis than other phospholipid types. Long-chain acyl-CoA synthetase 4 (ACSL4) can catalyze the esterification of arachidonic acid and adrenal acid into phosphatidylethanolamine (). Besides, ACSL4 binds free PUFAs to coenzyme A (CoA) to produce PUFA-CoAs, which then binds to PLs and blocks ferroptosis. Studies have shown that the inhibition of system Xc− uptake can inhibit the synthesis of glutathione (GSH) and glutathione peroxidase 4 (GPX4), leading to peroxide accumulation and ferroptosis (). GPX4 catalyzes the generation of non-toxic and low-reactivity lipid alcohols from PLOOHs to inhibit ROS production, which plays an important role in inhibiting ferroptosis (). Some lipid oxygenases (LOXs) are non-heme iron-dependent dioxygenases that directly oxidize PUFAs of biofilms, suggesting that LOXs may mediate the induction process of ferroptosis. Heme oxygenase 1 (HO-1)–mediated degradation of heme releases iron, which is closely related to ferroptosis (; ).
Iron is a central cofactor for several proteins involved in constitutive cell functions. Both iron deficiency and iron overload negatively affect physiology (). When the level of bioavailable iron is low, the body regulates the release of iron and supplemental ferritin through selective autophagy degradation (). When autophagy is activated, NCOA4 mediates the binding of ferritin to the lysosome, causing free iron to be released by degrading ferritin. This type of selective autophagy is known as “ferritinophagy” (). NCOA4 promotes the autophagic degradation of ferritin through direct binding, which results in the formation of ferritinophagy. In contrast, the inhibition of autophagy leads to the accumulation of NCOA4, which further confirms that NCOA4 is the autophagic receptor of ferritin (). Therefore, the proper maintenance of NCOA4 levels in cells is important for the regulation of ferritinophagy. Ferritinophagy causes increased intracellular iron levels and triggers the accumulation of ROS through the Fenton reaction, resulting in ferroptosis (). This cell death mode is closely related to the occurrence and development of many diseases (). Dysregulation of iron metabolism and ferroptosis have been observed in neurodegeneration, cancer, and infection; however, little is known regarding the role of ferritinophagy in the pathogenesis of these diseases. NCOA4-mediated ferritinophagy has been implicated in the maintenance of efficient erythropoiesis through iron release for mitochondrial heme synthesis. Recently, ferritinophagy has become an active area of research.
This study reviews the underlying mechanism of ferritinophagy and expounds the relationship between ferritinophagy and ferroptosis. The relationship between ferritinophagy and disease development is also discussed to provide a theoretical basis for future clinical and scientific research.
Regulatory mechanism of ferritinophagy
The multicellular process modifies the sensitivity of cells to ferroptosis by altering the intracellular unstable iron content. Iron uptake, storage, and export are strictly regulated, and the regulation of iron homeostasis provides a complete ferroptosis network. Increased iron uptake, decreased iron export, or decreased iron storage all can lead to iron overload and promote the occurrence and development of ferroptosis, and various iron chelating agents can inhibit ferroptosis (; ). At present, the factors regulating intracellular iron concentration mainly include the following: 1) iron uptake—extracellular Fe3+ binds to transferrin (Tf) and is located in endosomes by transferrin receptor (TfR1)–mediated endocytosis (). In the slightly acidic endosomal environment, Fe3+ is separated from Tf and reduced to Fe2+ by the metal reductase STEAP3 with the increase in pH. After reduction to Fe2+, non-transferrin-bound iron was directly transported to cell via divalent metal ion transporter 1 (DMT1) (). Heme iron is absorbed directly into cells by binding to heme carrier protein 1 (HCP1). In addition, the upregulation of nuclear factor erythroid 2–related factor 2 (Nrf2) activates HO-1, which leads to increased heme entry into the cytoplasm, heme degradation, and release of free iron from mitochondria (); 2) iron export—The part of Fe2+ in cytoplasm is stored in the form of ferritin, and the other part enters the circulation through ferroportin (Fpn/SLC40A1). After iron enters the circulation, it is oxidized by hephaestin or ceruloplasmin to Fe3+, which binds to transferrin. Additionally, ferritin can be transported by the Prominin-2 polyvesicle–exosome pathway out of the cell when the cell is overloaded with iron (; ; ); and 3) iron storage—Fe2+ enters the cells to form cytoplasmic labile iron pool (LIP) (; ). One part of Fe2+ is stored as ferritin, and the other part is used for various biochemical processes. Heme degradation and NCOA4-mediated autophagy can increase the instability of the LIP; intracellular accumulation of Fe2+ can be triggered by the Fenton reaction (; ; ). HO-1 is a rate-limiting enzyme in the process of heme degradation (), which catalyzes the oxidative degradation of heme and the release of free iron, carbon monoxide (CO), and biliverdin (). The activation of HO-1 leads to increased heme degradation and Fe2+-mediated ferritin expression, resulting in an increase in iron levels in LIP (). In the process of hemoglobin anabolism, Nrf2 regulates ferroptosis by regulating heme mobilization of iron during heme catabolism, promoting iron storage, reducing iron accumulation, and upregulating SLC7A11 activity to increase glutamate content (). Nrf2 is regulated by P62, which inhibits Nrf2 degradation and transcriptional function and downregulates SLC7A11 expression, thereby effectively inhibiting ferroptosis. HO-1 is highly expressed in organs responsible for the degradation of aged red blood cells, and HO-1 in macrophages is involved in the circulation of heme (). However, the overexpression of HO-1 promotes cancer cell proliferation and survival (). In addition, HO-1 induces angiogenesis by regulating the expression of angiogenic factors (). Other studies have shown that HO-1 knockout mice develop anemia associated with iron overload in the liver and kidney, resulting in oxidative tissue damage and chronic inflammation (; ). These findings indicate that HO-1 is not only involved in normal physiology but also has a role in pathophysiological states, and plays a dual regulatory role in ferroptosis () (Figure 1).
FIGURE 1
Ferritinophagy is a selective form of autophagy, and excessive ferritinophagy can induce ferroptosis (). Ferritin is the primary iron storage protein in the body, and its content and activity affect cellular iron levels. However, cells lacking NCOA4 cannot degrade ferritin, which results in a decrease in intracellular bioavailable iron. This suggests that NCOA4 is a selective cargo receptor for ferritin autophagy conversion, which is essential for iron homeostasis. NCOA4 is activated by the autophagy-related gene (ATG), which guides ferritin heavy chain (FTH) and ferritin light chain (FTL) to the autophagosome. The knockout of NCOA4 or ATG (ATG3, ATG5, ATG7, etc.) can significantly decrease ferritinophagy, iron overload, lipid peroxidation, and ferroptosis (). In addition, intracellular iron levels were regulated by ferrimodulin 1 (IRP1) and ferrimodulin 2 (IRP2) post-transcriptional levels (; ). The consumption of NCOA4 increases the level of IRP2, an RNA-binding protein that binds to a set of irreversible electroporation to regulate MMA. When iron content is sufficient, IRP1 contains Fe-S clusters and IRP2 degrades, thus inhibiting the IRP system (). When the IRP system is unable to maintain adequate levels of intracellular iron during severe iron deficiency, the iron preservation pathway is activated and involved in maintaining intracellular iron balance. In addition, NCOA4 mRNA is induced during erythropoiesis and its expression is associated with genes related to heme biosynthesis (). Traditionally, NCOA4-mediated ferritinophagy occurs in the cytoplasm; however, ferritin may also be degraded to induce iron poisoning and ferroptosis in the mitochondria. It is unknown whether or not this process depends on NCOA4 and the underlying mechanism of ferritin degradation in the mitochondria. Cytoplasmic free iron enters mitochondria through mitochondrial ferritin (MFRN), which is used for iron–sulfur clusters and heme biosynthesis (). Excess iron can be stored in a unique form in mitochondrial ferritin (FTMT) (). An increase in FTMT in hypoxic human macrophages is associated with decreased NCOA4 expression. NCOA4 expression may be reduced by impaired transcriptional regulation during hypoxia, and its mRNA is degraded by microRNA 6862-5p, whereas c-jun N-terminal kinase is involved in regulating the degradation of microRNA 6862-5p (). reported that the iron loss induces MFRN through the hypoxia-inducible factor 1α (HIF-1α)–specific protein 1 axis and triggers mitophagy for damaged mitochondria. Ferritinophagy maintains iron stability in vivo by regulating the release of free iron. When iron levels are low, the transferrin activity is increased, ferritinophagy is activated, and intracellular iron content increases in various ways. When iron levels are high, HERC2 binds to the C-terminus of NCOA4 through its Cullin 7 (CUL7) homology domain. This results in a decrease in NCOA4 in a ubiquitin-dependent manner, which inhibits ferritinophagy and blocks the release of iron from ferritin ().
In addition to ferritinophagy, other types of autophagy are associated with ferroptosis, such as lipophagy, clockophagy, and chaperone-mediated autophagy (CMA). Lipophagy is the process by which lipid droplets (LDs) in cells are selectively transported by the autophagosome for lysosome degradation. RAB7A is a cargo protein that mediates the degradation of LDs and plays an important role in regulating the autophagy lysosome. Enhancing tumor protein D52 (TPD52)–dependent lipid storage or blocking ATG5/RAB7A-dependent lipid degradation prevents RSL3-induced lipid peroxidation and subsequent ferroptosis in vitro and in vivo (). The overexpression of TPD52 promotes lipid storage and alleviates ferroptosis caused by RSL3. “Clockophagy,” the selective degradation of the core circadian clock protein, ARNTL, by autophagy, is necessary for ferroptosis. SQSTM1 acts as a cargo receptor for the degradation of autophagic ARNTL, which inhibits ferroptosis by repressing Egln2 transcription, thus activating the pro-survival transcription factor, HIF-1α. Therefore, the activation of the autophagy-dependent SQSTM1-ARNTL-EGLN2-HIF-1α pathway mediates lipid peroxidation and promotes ferroptosis (). CMA is a cellular lysosome-mediated degradative mechanism. HSP90 inhibits GPX4 degradation and promotes ferroptosis by regulating the stability of lysosomal surface proteins during CMA (). LAMP2A and HSPA8/HSC70 regulate CMA, which leads to erastin-induced GPX4 degradation in HT22 cells. In addition to selective autophagy, autophagy regulators (e.g., SLC7A11, BECN1, STAT3, Nrf2, p53, HSPB1, and ACSL4) also contribute to ferroptosis; however, the precise role of autophagy regulatory factors in ferroptosis remains unknown.
Ferritinophagy and related disease
As our understanding of ferroptosis/ferritinophagy increases, more studies have revealed that ferritinophagy-mediated ferroptosis is involved in the occurrence and development of neurological, infectious, cardiovascular, and cerebrovascular diseases and tumors. In contrast, the diseases induced by ferroptosis have a negative impact on human health. On the contrary, ferroptosis also represents a new anticancer strategy.
Ferritinophagy and neurodegenerative diseases
Iron plays an important role in DNA synthesis, mitochondrial respiration, and neurotransmitter synthesis, and changes in iron homeostasis in patients with neurodegenerative diseases (ND) are associated with decreased autophagy. Defects in the autophagy lysosomal pathway may be associated with the pathogenesis of ND, oxidative stress induces lysosome rupture in ferroptosis, whereas phagocytic vesicles formed during autophagy are bound to lysosomes and degraded. Currently, activating or inhibiting ferroptosis may be exploited to achieve therapeutic effects in ND ().
The death of dopaminergic neurons in the substantia nigra during PD is associated with the accumulation of iron (; ; ). PD is characterized by the depletion of dopamine neurons in the substantia nigra of the brain and abnormal aggregation of Lewy bodies, in which α-synuclein (α-syn) is regulated by iron during translation (). Iron directly interacts with α-syn in Lewy bodies, and α-syn is mainly digested through an autophagy lysosomal pathway, which not only responds to iron chelators and channels but also participates in the cellular iron cycle through the degradation of ferritin and other iron-containing components. These studies suggest that there is a relationship between iron deposition and autophagy injury during PD (). demonstrated that α-syn affects ferritinophagy by disrupting lysosome activity, thus leading to PD. This suggests that ferritinophagy may be involved in the progression of PD. Several PD causative or associated mutations involve proteins whose functions are associated with autophagy. PD-associated mutations in genes encoding parkin, PTEN-induced putative kinase 1, Parkinson protein 7, and HtrA serine peptidase 2 result in deficits in mitochondrial homeostasis and mitophagy pathway. RNA sequencing (RNA-seq) revealed that FTH1 was abnormally expressed in 6-hydroxydopamine (6-OHDA)–induced rat PD. In PC-12 cells, FTH1 overexpression downregulates NCOA4, inhibits ferritinophagy and ferroptosis, and ameliorates cell death. The autophagy inhibitors, chloroquine and bafilomycin A (1), can significantly inhibit ferritinophagy and ferroptosis in PC-12 cells treated with 6-OHDA (). Since redox-active iron is associated with the generation of ROS, inappropriate iron accumulation may be a key factor in the pathogenesis of PD.
HD (Huntington's disease) is an autosomal dominant ND characterized by a loss of motor control, loss of neurons in the striatum and cortex, and cognitive decline that leads to dementia. Both autophagy and CMA are either activated or impaired in patients with HD and animal models (). Koga observed an increased CMA activity in different cell and mouse models of HD.
AD is characterized by abnormal concentrations of β-amyloid and tau proteins inside and outside cells, which leads to neuronal dysfunction and neurodegeneration. Recent studies have shown that iron deposited in brain tissue is a pathogenic factor of AD and induces oxidative stress that leads to the death of nerve cells (). However, the relationship between iron homeostasis and the pathogenesis of AD remains unclear. Proteins involved in the pathogenesis of AD may contribute to the autophagy pathway or iron homeostasis. The autophagy lysosomal pathway appears to be significantly involved in the pathogenesis of AD, playing a pivotal role in the production and accumulation of amyloid plaques and neurofibrillary tangles. Furthermore, the stimulation of the autophagic clearance of protein aggregates is a potential therapeutic strategy to restore behavioral, learning, and memory deficits and limit AD progression ().
With the reduction in global autophagy observed in some ND, ferritin autophagy flow is also reduced. In vitro models of NCOA4 depletion indicate that bioavailable iron decreases as a result of reduced ferritin degradation, which leads to impaired iron release (). Studies on the role of autophagy in iron processing provide a new perspective on the role of iron in neurodegeneration, suggesting that autophagy dysregulation may lead to the dysregulation of iron homeostasis. Overall, further studies are needed to understand the role of NCOA4 in central nervous system development and the pathophysiology of iron-related ND.
Ferritinophagy and urinary tract infections
Ferroptosis induced by autophagy is an important regulatory pathway associated with vascular endothelial damage caused by inflammatory inducers (). Urinary tract infections (UTIs) are generally caused by uropathogenic Escherichia coli (UPEC) that persist in the urinary tract epithelial cells. Ferritin-bound iron to UPEC shuttles between the autophagosome and lysosomal compartments in the urinary tract epithelium. Iron is very important for the survival of host cells. Increasing the content of free iron in cells significantly increases the growth rate of the host cells. Therefore, a high dependence of UPEC on iron may be used as a novel strategy to defend against pathogens ().
first reported that NCOA4-dependent ferritinophagy triggers excessive proliferation and persistence of UPEC in host cells, which is caused by increased intracellular iron availability. Iron overload in urinary epithelial cells induces ferritinophagy in an NCOA4-dependent manner. This results in increased iron availability of UPEC, leading to excessive bacterial proliferation and host cell death. In addition, the lysosome damage caused by iron overload represents a specific mechanism that causes host cell death.
Ferritin phagocytosis promotes erythropoiesis and the development of UTIs as follows: 1) During iron deficiency, NCOA4 selectively interacts with the FTH1 subunit of ferritin through its C-terminal domain and arginine residues on FTH1. NCOA4 binds to PCBP1 and mediates ferritin flux, which is crucial for regulating heme synthesis and further erythrocyte differentiation. Concurrently, NCOA4-mediated ferritinophagy accelerates UTIs by increasing the availability of iron, thus enabling the persistence of UPEC in host cells. 2) In the case of adequate iron, HERC2 mediates the degradation of NCOA4 in a ubiquitin-dependent manner through the CUL7 homologous domain of HERC2 and the C-terminal domain of NCOA4, thus preventing ferritinophagy (). In addition, iron can promote the survival and growth of UPEC in host cells. (Table 1) demonstrated that free iron improves the growth rate of UPEC. Moreover, found that an increase in free iron caused by ferritinophagy also promotes the growth and survival of UPEC. UPEC may directly or indirectly drive ferritinophagy by depleting unstable iron pools and forcing UPEC to catabolize ferritin to provide iron for basic cellular functions. ATG16L1 protein is an autophagy-related protein. Studies have found that ATG16L1-deficient mice exhibit strong resistance to UPEC infection (). When free iron is removed by an iron-chelating agent, the growth rate of UPEC is significantly inhibited (). UPEC quiescent intracellular reservoirs in autophagosomes in vivo may lead to repeated infections as a result of UPEC following iron into autophagosomes, whereas UPEC is able to chelate iron through its siderophores.
TABLE 1
| Disease | Key mechanism | Reference | |
|---|---|---|---|
| Neurodegenerative diseases | Alzheimer's disease | Reduce free Fe2+ and lipid peroxides | |
| Parkinson's disease | Reduce free Fe2+ and lipid peroxides | ; | |
| Huntington's disease | Inhibit Nrf2 degradation | ||
| Infectious disease | Urinary tract infections | Inhibit iron accumulation | ; |
| Cardiocerebrovascular diseases | Dox-induced cardiac injury | Inhibit Nrf2 degradation Block lipid peroxidation | ; |
| Heart failure | Reduce Fe2+ and lipid peroxides | ; | |
| Atherosclerosis | Reduce Fe2+ and lipid peroxides | ||
| Lung cancer | Reduce free Fe2+ and lipid peroxides Inactivation of GPX4 | ||
| Liver cancer | Activate Nrf2 pathway Increase free Fe2+ and lipid peroxides | ||
| Colorectal cancer | Suppress system Xc− Increase free Fe2+ and lipid peroxides | ||
| Cancer | Glioblastoma | Block iron transport Increase free Fe2+ and lipid peroxides | : |
| Breast cancer | Block iron transport; Increase free Fe2+ and lipid peroxides | ; | |
| Pancreas cancer | Suppress system Xc− Block iron transport | ||
| Ovarian cancer | Inhibit system Xc− activity | ||
Treatment strategies of ferritinophagy-mediated ferroptosis in related diseases.
Therefore, the regulation of ferritinophagy may have certain clinical value to reduce the persistence of UPEC and prevent the recurrence of UTI (). Interrupting ferritinophagy to control iron levels may provide a potentially therapeutic avenue to suppress UTI.
Ferritinophagy and cardiocerebrovascular diseases
Both iron deficiency and iron overload are associated with cardiomyopathy an heart failure through complex mechanisms (). Excessive iron accumulation in the heart leads to iron overload cardiomyopathy, the leading cause of death in patients with hemochromatosis (). In a doxorubicin (Dox)-induced cardiomyopathy mouse model, RNA-seq analysis revealed differentially expressed genes, including HO-1 significantly upregulated (). Iron overload was found in liver and kidney in HO-1 knockout mice, and the inhibition of HO-1 by zinc protoporphyrin IX reversed Dox-induced ferroptosis (). Previous studies have reported that iron overload leads to cardiac mitochondrial dysfunction, which is primarily manifested by reduced mitochondrial respiration, increased mitochondrial ROS levels, and low mitochondrial swelling (). Dox-induced cardiomyopathy mainly triggered a significant increase in the level of peroxidized phosphatidylethanolamine in mitochondria (). The above result further highlights the heart mitochondria in the role of lipid peroxide produced (; ). Studies have shown that lipopolysaccharide (LPS)-induced myocardial injury in a mouse sepsis model is closely associated with ferroptosis. found that after LPS treatment, the level of ferritinophagy was enhanced, and the mRNA expression and protein expression of sideroflexin 1 (SFXN1) were increased. A large amount of Fe2+ binds with SFXN1 and is transported to mitochondria, where a large amount of ROS is produced by the Fenton reaction and promotes the occurrence of ferroptosis. In in vitro experiments, LPS can increase the expression of NOCA4, promote ferritinophagy, and increase the release of free iron to cause lipid peroxidation, which may be one of the ferroptosis mechanisms that occurs in myocardial cells (). The deletion of NCOA4 in mouse hearts improved cardiac function along with the attenuation of the upregulation of ferritinophagy-mediated ferritin degradation after stress overload (; ). Ferrostatin-1 did not provide additional protection from pressure overload–induced cardiac remodeling in NCOA4−/− mice, suggesting that iron-dependent cardiomyocyte death is downstream of NCOA4-mediated ferritinophagy. Toll-like receptor 4 and NADPH oxidase 4 knockdown can delay hyperactivated autophagy and ferroptosis ().
Abnormal lipid metabolism, oxidative stress, and inflammation are the main features of atherosclerosis (AS) (). The Nrf2-Keap1 pathway decreases ferroptosis associated with AS by maintaining cellular iron homeostasis, increasing the production of glutathione, GPX4, and NADPH. The overexpression of GPX4 in apolipoprotein E knockout (ApoE−/−) mice attenuates the upregulation of endothelial cell adhesion molecule and monocyte–endothelial cell adhesion, thereby inhibiting the development of AS (). It has been reported that chronic iron overload could exacerbate the AS in ApoE−/− mice by inducing oxidative stress and endothelial dysfunction (; ). Zinc oxide nanoparticles (ZNOPs) exhibit various activities in biomedicine. They can be used as drug carriers but can be cytotoxic to vascular endothelial cells, thus aggravating vascular injury. Studies have shown that ZNOPs can lead to ferroptosis in vascular endothelial cells, whereas NCOA4 knockdown can reduce intracellular iron and lipid peroxidation. It was demonstrated that ZNOPs may lead to ferroptosis of endothelial cells through ferritinophagy (). Iron overload induces endothelial dysfunction by enhancing oxidative and inflammatory responses of endothelial cells (), revealing the potential relationship between ferritinophagy-induced ferroptosis and AS.
Ischemic stroke is a complex brain disease that is regulated by multiple pathways of cell death, including autophagy and ferroptosis. However, the potential association between autophagy and ferroptosis during ischemic stroke has not been determined. Since the destruction of iron homeostasis and autophagy defects coexist in ischemic stroke and autophagy promotes the clearance of toxic proteins to maintain cell homeostasis, we postulate that abnormal autophagy is likely to mediate the degradation of ferritin, thus promoting iron overload and ferroptosis during ischemic stroke (). NCOA4 may play a role in FTH1 conversion in the brain (). High serum ferritin content is also associated with poor prognosis during ischemic stroke (), suggesting that ferritin plays an important role in mediating iron storage and release. TfR1 is a major receptor involved in iron transport to the brain, which plays an important role in maintaining iron homeostasis and regulating iron atonia. Thus, the inhibition of ferroptosis by inhibiting free Fe2+, and reducing ROS accumulation and lipid peroxidation may provide a new approach to the treatment of ischemic stroke.
Ferritinophagy and cancer
Normal iron metabolism is a marker of abnormal expression in many cancers. Intracellular ferritin imbalance is closely associated with the development of cancer, and there is increasing evidence that ferritinophagy and ferroptosis play an important role in tumor therapy (, ). NCOA4 may be relevant to carcinogenesis, and the intersection of ferritinophagy and ferroptosis pathways may represent a therapeutic approach (). A positive correlation between NCOA4 mRNA and NCOA4α protein levels and transformation has been reported in ovarian carcinoma. The expression and function of NCOA4 isoforms have been reported in transformed endometriotic and malignant ovarian cancer cells (). The overexpression of several oncogenes (MYC, H-Ras, and p53 inactivation) in normal endometriotic cells to induce transformation resulted in an upregulation of NCOA4α and NCOA4β expression. NCOA4α knockdown in transformed cells decreased survival, whereas NCOA4β overexpression decreased colony formation. In contrast, in studies of prostate cancer, NCOA4α acts as a tumor suppressor, whereas NCOA4β expression correlated with proliferation and invasion. The prostate cancer cell proliferation and invasion was stimulated by the androgen receptor coactivator, androgen receptor-associated protein 70 (). NCOA4-mediated ferritinophagy promotes ferroptosis induced by erastin, but not by RSL3 in HeLa cells. Ferritinophagy is required for the induction of ferroptosis by the bromodomain protein, bromodomain-containing protein 4 inhibitor (+)-JQ1, in cancer cells. Low expression of the ferritinophagy-related NCOA4 gene was related to unfavorable outcomes and defective immune cell infiltration in clear cell renal carcinoma. Lipid peroxidation–mediated ferroptosis has recently attracted widespread attention as a potential therapeutic strategy for cancer. Zeta1 (COPZ1), the complex subunit of the coat protein, is a putative therapeutic target for glioblastoma, which can significantly affect iron metabolism and tumor prognosis. The COPZ1-NCOA4-FTH1 axis may represent a new target for the treatment of glioblastoma (). Pancreatic cancer cell lines have increased NCOA4 levels and a corresponding high flux through the ferritinophagy pathway. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy (). Direct evidence for the role of NCOA4 in modulating ferroptotic cell death in pancreatic cancer cells was provided by Yang et al. who showed that artesunate-mediated ferroptotic cell death is attenuated by NCOA4 depletion ().
System Xc− is the main active site for erastin, which was first screened for its ability to kill tumor cells with almost no toxicity against homologous normal cells with Ras mutations (). SLC7A11 is overexpressed in various malignant tumors and is closely related to the growth, prognosis, metastasis, and treatment of malignant tumors including breast, ovarian, liver, and lung cancers. RNA-binding protein (RBP) plays a role in the regulation of gene expression. Yang et al. found that RBP, RBMS1, affects ferroptosis in lung cancer by regulating the translation of SLC7A11. NTP can lead to the downregulation of RBMS1 in radiotherapy-resistant cells, thus reducing the expression of SLC7A11 and promoting the ferroptosis. This renders radiotherapy-resistant lung cancer cells sensitive to radiotherapy and provides a new treatment for lung cancer patients (). Xue et al. demonstrated an important role of micronutrient iron in colorectal cancer growth. Conversely, ferritinophagy is not required for colon cancer cell growth. Compared with other tissues, the gut is a major tissue that is essential for normal dietary iron absorption. Therefore, it contains several mechanisms that regulate apical iron transport and basolateral outflow. demonstrated a marginal role for ferritinophagy in growth under normal and cytotoxic conditions in colon cancer cells, as well as a possible compensatory mechanism in response to ferroptosis. This study demonstrated that ferritinophagy is not required for the basal growth of colorectal cancer (CRC)–derived cells. The main reason is that an increased ability of colon cancer cells to uptake iron from the extracellular environment may compensate for the loss of NCOA4 function through the exclusive use of extracellular iron for survival. In addition, an increase in Ftn protein expression may also serve as a protective mechanism by sequestering the iron needed for cell death and ferroptosis into Ftn. CRC pathogenesis is dependent upon iron. TfR1 expression has also been found to be high in CRC tissues and CRC-derived cell lines. Its downregulation promotes cancer progression, which underscores the role of transferrin-bound iron uptake in tumor growth ().
Intracellular ROS imbalance–mediated oxidative stress defense is also closely related to drug resistance in tumors. Currently, acquired resistance to chemotherapy is a major cause of tumor progression. Iron overload in tumor cells catalyzes the production of ROS and meets the needs of cell proliferation to a certain extent; however, when tumor cells are exposed to chemotherapeutic drugs, ROS production is induced (). The sensitivity of K562 leukemia cells to doxorubicin may be increased by treating it with the iron-chelating agent, deferoxamine (DFO), to inhibit iron overload. DFO treatment of cervical cancer cells enhances their sensitivity to oxaliplatin, providing direct evidence that iron overload is involved in chemotherapeutic drug resistance (). DFO treatment of different types of ovarian cancer cells significantly increases intracellular iron ions and ROS (). Recent studies showed that the nuclear transcription factor, Nrf2, is closely associated with the regulation of ferroptosis and the inhibition of the Nrf2-Keap1 signaling pathway activation promotes ferroptosis and reverses drug resistance in cisplatin-resistant head and neck tumors (). Sorafenib, a targeted therapy for liver cancer, is a strong inducer of ferroptosis. The activation of the Nrf2 pathway in liver cancer cells can upregulate the expression of metallothionein-1G (MT-1G) and promotes sorafenib drug resistance by inhibiting ferroptosis (). Therefore, triggering ferroptosis in cancer with high autophagy levels may reveal a potential vulnerability. One possible therapeutic strategy is to increase iron flux through the ferritinophagy pathway, leading to increased labile iron and ROS and sensitizing cancer cells to ferroptosis-inducing agents. Thus, inducing autophagy-dependent ferroptosis may represent a new antitumor strategy.
Conclusion and perspective
Ferritinophagy is an important mechanism that regulates iron levels in vivo. It has been demonstrated that ferritinophagy is closely related to nervous system diseases, tumors, and infectious diseases. Although the molecular mechanism of ferritinophagy remains undefined, the inhibition of ferritinophagy can prevent and reverse various diseases. Further research on the mechanism of ferritinophagy is expected to provide a theoretical basis for the treatment of related diseases in the future.
Statements
Author contributions
Conception and design: All authors; Administrative support: All authors; Provision of study materials or patients: All authors; Collection and assembly of data: All authors; Data analysis and interpretation: All authors; Manuscript writing: All authors; Final approval of manuscript: All authors.
Funding
This work was supported by the National Natural Science Foundation of China (81670260 and 81871596) and the Shanghai Biomedical Science and Technology Support Program (20S190280).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
BaiY.MengL.HanL.JiaY.ZhaoY.GaoH.et al (2019). Lipid storage and lipophagy regulates ferroptosis. Biochem. Biophys. Res. Commun.508, 997–1003. 10.1016/j.bbrc.2018.12.039PubMed Abstract | CrossRef Full Text | Google Scholar
2
BaksiS.SinghN. (2017). α-Synuclein impairs ferritinophagy in the retinal pigment epithelium: Implications for retinal iron dyshomeostasis in Parkinson's disease. Sci. Rep.7, 12843. 10.1038/s41598-017-12862-xPubMed Abstract | CrossRef Full Text | Google Scholar
3
BauckmanK. A.MysorekarI. U. (2016). Ferritinophagy drives uropathogenic Escherichia coli persistence in bladder epithelial cells. Autophagy12, 850–863. 10.1080/15548627.2016.1160176PubMed Abstract | CrossRef Full Text | Google Scholar
4
BauckmanK. A.Owusu-BoaiteyN.MysorekarI. U. (2015). Selective autophagy: xenophagy. Methods75, 120–127. 10.1016/j.ymeth.2014.12.005PubMed Abstract | CrossRef Full Text | Google Scholar
5
BayevaM.ChangH. C.WuR.ArdehaliH. (2013). When less is more: novel mechanisms of iron conservation. Trends Endocrinol. Metab.24, 569–577. 10.1016/j.tem.2013.07.003PubMed Abstract | CrossRef Full Text | Google Scholar
6
BellelliR.FedericoG.MatteA.ColecchiaD.IolasconA.ChiarielloM.et al (2016). NCOA4 deficiency impairs systemic iron homeostasis. Cell Rep.14, 411–421. 10.1016/j.celrep.2015.12.065PubMed Abstract | CrossRef Full Text | Google Scholar
7
BiasiottoG.Di LorenzoD.ArchettiS.ZanellaI. (2016). Iron and neurodegeneration: Is ferritinophagy the link?Mol. Neurobiol.53, 5542–5574. 10.1007/s12035-015-9473-yPubMed Abstract | CrossRef Full Text | Google Scholar
8
BrumbaughA. R.SmithS. N.MobleyH. L. (2013). Immunization with the yersiniabactin receptor, FyuA, protects against pyelonephritis in a murine model of urinary tract infection. Infect. Immun.81, 3309–3316. 10.1128/iai.00470-13PubMed Abstract | CrossRef Full Text | Google Scholar
9
BulvikB. E.BerenshteinE.Meyron-HoltzE. G.KonijnA. M.ChevionM. (2012). Cardiac protection by preconditioning is generated via an iron-signal created by proteasomal degradation of iron proteins. PLoS One7, e48947. 10.1371/journal.pone.0048947PubMed Abstract | CrossRef Full Text | Google Scholar
10
CampanellaA.RovelliE.SantambrogioP.CozziA.TaroniF.LeviS. (2009). Mitochondrial ferritin limits oxidative damage regulating mitochondrial iron availability: hypothesis for a protective role in friedreich ataxia. Hum. Mol. Genet.18, 1–11. 10.1093/hmg/ddn308PubMed Abstract | CrossRef Full Text | Google Scholar
11
ChenS. J.KuoC. C.PanH. Y.TsouT. C.YehS. C.ChangJ. Y. (2016). Desferal regulates hCtr1 and transferrin receptor expression through Sp1 and exhibits synergistic cytotoxicity with platinum drugs in oxaliplatin-resistant human cervical cancer cells in vitro and in vivo. Oncotarget7, 49310–49321. 10.18632/oncotarget.10336PubMed Abstract | CrossRef Full Text | Google Scholar
12
ChenX.YuC.KangR.TangD. (2020). Iron metabolism in ferroptosis. Front. Cell Dev. Biol.8, 590226. 10.3389/fcell.2020.590226PubMed Abstract | CrossRef Full Text | Google Scholar
13
ChenL. L.HuangY. J.CuiJ. T.SongN.XieJ. (2019). Iron dysregulation in Parkinson's disease: Focused on the autophagy-lysosome pathway. ACS Chem. Neurosci.10, 863–871. 10.1021/acschemneuro.8b00390PubMed Abstract | CrossRef Full Text | Google Scholar
14
ChenX.XuS.ZhaoC.LiuB. (2019). Role of TLR4/NADPH oxidase 4 pathway in promoting cell death through autophagy and ferroptosis during heart failure. Biochem. Biophys. Res. Commun.516, 37–43. 10.1016/j.bbrc.2019.06.015PubMed Abstract | CrossRef Full Text | Google Scholar
15
ChiangS. K.ChenS. E.ChangL. C. (2018). A dual role of heme oxygenase-1 in cancer cells. Int. J. Mol. Sci.20, E39. 10.3390/ijms20010039PubMed Abstract | CrossRef Full Text | Google Scholar
16
ChoiY. K.KimY. M. (2022). Beneficial and detrimental roles of heme oxygenase-1 in the neurovascular system. Int. J. Mol. Sci.23, 7041. 10.3390/ijms23137041PubMed Abstract | CrossRef Full Text | Google Scholar
17
ConradM.PronethB. (2019). Broken hearts: Iron overload, ferroptosis and cardiomyopathy. Cell Res.29, 263–264. 10.1038/s41422-019-0150-yPubMed Abstract | CrossRef Full Text | Google Scholar
18
CuiC.ChengX.YanL.DingH.GuanX.ZhangW.et al (2019). Downregulation of TfR1 promotes progression of colorectal cancer via the JAK/STAT pathway. Cancer Manag. Res.11, 6323–6341. 10.2147/cmar.S198911PubMed Abstract | CrossRef Full Text | Google Scholar
19
DollS.ConradM. (2017). Iron and ferroptosis: A still ill-defined liaison. IUBMB Life69, 423–434. 10.1002/iub.1616PubMed Abstract | CrossRef Full Text | Google Scholar
20
DongH.QiangZ.ChaiD.PengJ.XiaY.HuR.et al (2020). Nrf2 inhibits ferroptosis and protects against acute lung injury due to intestinal ischemia reperfusion via regulating SLC7A11 and HO-1. Aging (Albany NY)12, 12943–12959. 10.18632/aging.103378PubMed Abstract | CrossRef Full Text | Google Scholar
21
DrummondG. S.BaumJ.GreenbergM.LewisD.AbrahamN. G. (2019). HO-1 overexpression and underexpression: Clinical implications. Arch. Biochem. Biophys.673, 108073. 10.1016/j.abb.2019.108073PubMed Abstract | CrossRef Full Text | Google Scholar
22
ElingN.ReuterL.HazinJ.Hamacher-BradyA.BradyN. R. (2015). Identification of artesunate as a specific activator of ferroptosis in pancreatic cancer cells. Oncoscience2, 517–532. 10.18632/oncoscience.160PubMed Abstract | CrossRef Full Text | Google Scholar
23
FacchinettiM. M. (2020). Heme-Oxygenase-1. Antioxid. Redox Signal.32, 1239–1242. 10.1089/ars.2020.8065PubMed Abstract | CrossRef Full Text | Google Scholar
24
FangX.WangH.HanD.XieE.YangX.WeiJ.et al (2019). Ferroptosis as a target for protection against cardiomyopathy. Proc. Natl. Acad. Sci. U. S. A.116, 2672–2680. 10.1073/pnas.1821022116PubMed Abstract | CrossRef Full Text | Google Scholar
25
FangX.CaiZ.WangH.HanD.ChengQ.ZhangP.et al (2020). Loss of cardiac ferritin H facilitates cardiomyopathy via slc7a11-mediated ferroptosis. Circ. Res.127, 486–501. 10.1161/circresaha.120.316509PubMed Abstract | CrossRef Full Text | Google Scholar
26
FangX.ArdehaliH.MinJ.WangF. (2022). The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease. Nat. Rev. Cardiol.1–17. 10.1038/s41569-022-00735-4CrossRef Full Text | Google Scholar
27
FebbraroF.GiorgiM.CaldarolaS.LoreniF.Romero-RamosM. (2012). α-Synuclein expression is modulated at the translational level by iron. Neuroreport23, 576–580. 10.1097/WNR.0b013e328354a1f0PubMed Abstract | CrossRef Full Text | Google Scholar
28
FengH.SchorppK.JinJ.YozwiakC. E.HoffstromB. G.DeckerA. M.et al (2020). Transferrin receptor is a specific ferroptosis marker. Cell Rep.30, 3411–3423. 10.1016/j.celrep.2020.02.049PubMed Abstract | CrossRef Full Text | Google Scholar
29
FengJ.LiC.XuR.LiY.HouQ.FengR.et al (2020). DpdtC-induced EMT inhibition in MGC-803 cells was partly through ferritinophagy-mediated ROS/p53 pathway. Oxid. Med. Cell. Longev.2020, 9762390. 10.1155/2020/9762390PubMed Abstract | CrossRef Full Text | Google Scholar
30
Flores-MirelesA. L.WalkerJ. N.CaparonM.HultgrenS. J. (2015). Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat. Rev. Microbiol.13, 269–284. 10.1038/nrmicro3432PubMed Abstract | CrossRef Full Text | Google Scholar
31
FuhrmannD. C.MondorfA.BeifußJ.JungM.BrüneB. (2020). Hypoxia inhibits ferritinophagy, increases mitochondrial ferritin, and protects from ferroptosis. Redox Biol.36, 101670. 10.1016/j.redox.2020.101670PubMed Abstract | CrossRef Full Text | Google Scholar
32
GaladariS.RahmanA.PallichankandyS.ThayyullathilF. (2017). Reactive oxygen species and cancer paradox: To promote or to suppress?Free Radic. Biol. Med.104, 144–164. 10.1016/j.freeradbiomed.2017.01.004PubMed Abstract | CrossRef Full Text | Google Scholar
33
GammellaE.RecalcatiS.CairoG. (2016). Dual role of ROS as signal and stress agents: Iron tips the balance in favor of toxic effects. Oxid. Med. Cell. Longev.2016, 8629024. 10.1155/2016/8629024PubMed Abstract | CrossRef Full Text | Google Scholar
34
GaoM.MonianP.PanQ.ZhangW.XiangJ.JiangX. (2016). Ferroptosis is an autophagic cell death process. Cell Res.26, 1021–1032. 10.1038/cr.2016.95PubMed Abstract | CrossRef Full Text | Google Scholar
35
García-YébenesI.SobradoM.MoragaA.ZarrukJ. G.RomeraV. G.PradilloJ. M.et al (2012). Iron overload, measured as serum ferritin, increases brain damage induced by focal ischemia and early reperfusion. Neurochem. Int.61, 1364–1369. 10.1016/j.neuint.2012.09.014PubMed Abstract | CrossRef Full Text | Google Scholar
36
GriffithsR. E.KupzigS.CoganN.MankelowT. J.BetinV. M.TrakarnsangaK.et al (2012). The ins and outs of human reticulocyte maturation: autophagy and the endosome/exosome pathway. Autophagy8, 1150–1151. 10.4161/auto.20648PubMed Abstract | CrossRef Full Text | Google Scholar
37
GuoZ.RanQ.RobertsL. J.2ndZhouL.RichardsonA.SharanC.et al (2008). Suppression of atherogenesis by overexpression of glutathione peroxidase-4 in apolipoprotein E-deficient mice. Free Radic. Biol. Med.44, 343–352. 10.1016/j.freeradbiomed.2007.09.009PubMed Abstract | CrossRef Full Text | Google Scholar
38
HabasK.ShangL. (2018). Alterations in intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1) in human endothelial cells. Tissue Cell54, 139–143. 10.1016/j.tice.2018.09.002PubMed Abstract | CrossRef Full Text | Google Scholar
39
HaraY.YanatoriI.TanakaA.KishiF.LemastersJ. J.NishinaS.et al (2020). Iron loss triggers mitophagy through induction of mitochondrial ferritin. EMBO Rep.21, e50202. 10.15252/embr.202050202PubMed Abstract | CrossRef Full Text | Google Scholar
40
HasanM.ReddyS. M.DasN. K. (2020). Ferritinophagy is not required for colon cancer cell growth. Cell Biol. Int.44, 2307–2314. 10.1002/cbin.11439PubMed Abstract | CrossRef Full Text | Google Scholar
41
HouW.XieY.SongX.SunX.LotzeM. T.ZehH. J.et al (2016). Autophagy promotes ferroptosis by degradation of ferritin. Autophagy12, 1425–1428. 10.1080/15548627.2016.1187366PubMed Abstract | CrossRef Full Text | Google Scholar
42
HuangY.YangY.XuY.MaQ.GuoF.ZhaoY.et al (2021). Nrf2/HO-1 Axis regulates the angiogenesis of gastric cancer via targeting VEGF. Cancer Manag. Res.13, 3155–3169. 10.2147/cmar.S292461PubMed Abstract | CrossRef Full Text | Google Scholar
43
ItoJ.OmiyaS.RusuM. C.UedaH.MurakawaT.TanadaY.et al (2021). Iron derived from autophagy-mediated ferritin degradation induces cardiomyocyte death and heart failure in mice. Elife10, e62174. 10.7554/eLife.62174PubMed Abstract | CrossRef Full Text | Google Scholar
44
JangS.Chapa-DubocqX. R.TyurinaY. Y.St CroixC. M.KapralovA. A.TyurinV. A.et al (2021). Elucidating the contribution of mitochondrial glutathione to ferroptosis in cardiomyocytes. Redox Biol.45, 102021. 10.1016/j.redox.2021.102021PubMed Abstract | CrossRef Full Text | Google Scholar
45
JiangH.WangJ.RogersJ.XieJ. (2017). Brain iron metabolism dysfunction in Parkinson's disease. Mol. Neurobiol.54, 3078–3101. 10.1007/s12035-016-9879-1PubMed Abstract | CrossRef Full Text | Google Scholar
46
JiangX.StockwellB. R.ConradM. (2021). Ferroptosis: mechanisms, biology and role in disease. Nat. Rev. Mol. Cell Biol.22, 266–282. 10.1038/s41580-020-00324-8PubMed Abstract | CrossRef Full Text | Google Scholar
47
KakhlonO.CabantchikZ. I. (2002). The labile iron pool: characterization, measurement, and participation in cellular processes(1). Free Radic. Biol. Med.33, 1037–1046. 10.1016/s0891-5849(02)01006-7PubMed Abstract | CrossRef Full Text | Google Scholar
48
KhamseekaewJ.KumfuS.WongjaikamS.KerdphooS.JaiwongkamT.SrichairatanakoolS.et al (2017). Effects of iron overload, an iron chelator and a T-Type calcium channel blocker on cardiac mitochondrial biogenesis and mitochondrial dynamics in thalassemic mice. Eur. J. Pharmacol.799, 118–127. 10.1016/j.ejphar.2017.02.015PubMed Abstract | CrossRef Full Text | Google Scholar
49
KhasheiiB.AnvariS.JamalliA. (2016). Frequency evaluation of genes encoding siderophores and the effects of different concentrations of Fe ions on growth rate of uropathogenic Escherichia coli. Iran. J. Microbiol.8, 359–365. PubMed Abstract | Google Scholar
50
LawsonD. M.ArtymiukP. J.YewdallS. J.SmithJ. M.LivingstoneJ. C.TreffryA.et al (1991). Solving the structure of human H ferritin by genetically engineering intermolecular crystal contacts. Nature349, 541–544. 10.1038/349541a0PubMed Abstract | CrossRef Full Text | Google Scholar
51
LiW.FengG.GauthierJ. M.LokshinaI.HigashikuboR.EvansS.et al (2019). Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation. J. Clin. Invest.129, 2293–2304. 10.1172/jci126428PubMed Abstract | CrossRef Full Text | Google Scholar
52
LiH. B.ZhangX. Z.SunY.ZhouQ.SongJ. N.HuZ. F.et al (2020). HO-1/PINK1 regulated mitochondrial fusion/fission to inhibit pyroptosis and attenuate septic acute kidney injury. Biomed. Res. Int.2020, 2148706. 10.1155/2020/2148706PubMed Abstract | CrossRef Full Text | Google Scholar
53
LiJ.CaoF.YinH. L.HuangZ. J.LinZ. T.MaoN.et al (2020). Ferroptosis: past, present and future. Cell Death Dis.11, 88. 10.1038/s41419-020-2298-2PubMed Abstract | CrossRef Full Text | Google Scholar
54
LiN.WangW.ZhouH.WuQ.DuanM.LiuC.et al (2020). Ferritinophagy-mediated ferroptosis is involved in sepsis-induced cardiac injury. Free Radic. Biol. Med.160, 303–318. 10.1016/j.freeradbiomed.2020.08.009PubMed Abstract | CrossRef Full Text | Google Scholar
55
LiuJ.GuoZ. N.YanX. L.HuangS.RenJ. X.LuoY.et al (2020). Crosstalk between autophagy and ferroptosis and its putative role in ischemic stroke. Front. Cell. Neurosci.14, 577403. 10.3389/fncel.2020.577403PubMed Abstract | CrossRef Full Text | Google Scholar
56
LiuX. J.LvY. F.CuiW. Z.LiY.LiuY.XueY. T.et al (2021). Icariin inhibits hypoxia/reoxygenation-induced ferroptosis of cardiomyocytes via regulation of the Nrf2/HO-1 signaling pathway. FEBS Open Bio11, 2966–2976. 10.1002/2211-5463.13276PubMed Abstract | CrossRef Full Text | Google Scholar
57
MaH.WangX.ZhangW.LiH.ZhaoW.SunJ.et al (2020). Melatonin suppresses ferroptosis induced by high glucose via activation of the Nrf2/HO-1 signaling pathway in type 2 diabetic osteoporosis. Oxid. Med. Cell. Longev.2020, 9067610. 10.1155/2020/9067610PubMed Abstract | CrossRef Full Text | Google Scholar
58
MaL. L.SunL.WangY. X.SunB. H.LiY. F.JinY. L. (2022). Association between HO-1 gene promoter polymorphisms and diseases (Review). Mol. Med. Rep.25, 29. 10.3892/mmr.2021.12545PubMed Abstract | CrossRef Full Text | Google Scholar
59
ManciasJ. D.WangX.GygiS. P.HarperJ. W.KimmelmanA. C. (2014). Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature509, 105–109. 10.1038/nature13148PubMed Abstract | CrossRef Full Text | Google Scholar
60
ManciasJ. D.Pontano VaitesL.NissimS.BiancurD. E.KimA. J.WangX.et al (2015). Ferritinophagy via NCOA4 is required for erythropoiesis and is regulated by iron dependent HERC2-mediated proteolysis. Elife4. 10.7554/eLife.10308PubMed Abstract | CrossRef Full Text | Google Scholar
61
MarquesV. B.LealM. A. S.MageskiJ. G. A.FidelisH. G.NogueiraB. V.VasquezE. C.et al (2019). Chronic iron overload intensifies atherosclerosis in apolipoprotein E deficient mice: Role of oxidative stress and endothelial dysfunction. Life Sci.233, 116702. 10.1016/j.lfs.2019.116702PubMed Abstract | CrossRef Full Text | Google Scholar
62
McColganP.TabriziS. J. (2018). Huntington's disease: a clinical review. Eur. J. Neurol.25, 24–34. 10.1111/ene.13413PubMed Abstract | CrossRef Full Text | Google Scholar
63
MenaN. P.UrrutiaP. J.LouridoF.CarrascoC. M.NúñezM. T. (2015). Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders. Mitochondrion21, 92–105. 10.1016/j.mito.2015.02.001PubMed Abstract | CrossRef Full Text | Google Scholar
64
MoroishiT.YamauchiT.NishiyamaM.NakayamaK. I. (2014). HERC2 targets the iron regulator FBXL5 for degradation and modulates iron metabolism. J. Biol. Chem.289, 16430–16441. 10.1074/jbc.M113.541490PubMed Abstract | CrossRef Full Text | Google Scholar
65
PengY.LiC. X.ChenF.WangZ.LigrM.MelamedJ.et al (2008). Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. Am. J. Pathol.172, 225–235. 10.2353/ajpath.2008.070065PubMed Abstract | CrossRef Full Text | Google Scholar
66
QinX.ZhangJ.WangB.XuG.YangX.ZouZ.et al (2021). Ferritinophagy is involved in the zinc oxide nanoparticles-induced ferroptosis of vascular endothelial cells. Autophagy17, 4266–4285. 10.1080/15548627.2021.1911016PubMed Abstract | CrossRef Full Text | Google Scholar
67
RockfieldS.FloresI.NanjundanM. (2018). Expression and function of nuclear receptor coactivator 4 isoforms in transformed endometriotic and malignant ovarian cells. Oncotarget9, 5344–5367. 10.18632/oncotarget.23747PubMed Abstract | CrossRef Full Text | Google Scholar
68
RohJ. L.KimE. H.JangH.ShinD. (2017). Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis. Redox Biol.11, 254–262. 10.1016/j.redox.2016.12.010PubMed Abstract | CrossRef Full Text | Google Scholar
69
RouaultT. A. (2006). The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat. Chem. Biol.2, 406–414. 10.1038/nchembio807PubMed Abstract | CrossRef Full Text | Google Scholar
70
Santana-CodinaN.GableskeS.Quiles del ReyM.MałachowskaB.JedrychowskiM. P.BiancurD. E.et al (2019). NCOA4 maintains murine erythropoiesis via cell autonomous and non-autonomous mechanisms. Haematologica104, 1342–1354. 10.3324/haematol.2018.204123PubMed Abstract | CrossRef Full Text | Google Scholar
71
ShawP. A.RittenbergP. V.BrownT. J. (2001). Activation of androgen receptor-associated protein 70 (ARA70) mRNA expression in ovarian cancer. Gynecol. Oncol.80, 132–138. 10.1006/gyno.2000.6068PubMed Abstract | CrossRef Full Text | Google Scholar
72
SongN.XieJ. (2018). Iron, dopamine, and α-synuclein interactions in at-risk dopaminergic neurons in Parkinson's disease. Neurosci. Bull.34, 382–384. 10.1007/s12264-018-0209-7PubMed Abstract | CrossRef Full Text | Google Scholar
73
SongY.WangB.ZhuX.HuJ.SunJ.XuanJ.et al (2021). Human umbilical cord blood-derived MSCs exosome attenuate myocardial injury by inhibiting ferroptosis in acute myocardial infarction mice. Cell Biol. Toxicol.37, 51–64. 10.1007/s10565-020-09530-8PubMed Abstract | CrossRef Full Text | Google Scholar
74
StockwellB. R.Friedmann AngeliJ. P.BayirH.BushA. I.ConradM.DixonS. J.et al (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell171, 273–285. 10.1016/j.cell.2017.09.021PubMed Abstract | CrossRef Full Text | Google Scholar
75
SumneangN.Siri-AngkulN.KumfuS.ChattipakornS. C.ChattipakornN. (2020). The effects of iron overload on mitochondrial function, mitochondrial dynamics, and ferroptosis in cardiomyocytes. Arch. Biochem. Biophys.680, 108241. 10.1016/j.abb.2019.108241PubMed Abstract | CrossRef Full Text | Google Scholar
76
TadokoroT.IkedaM.IdeT.DeguchiH.IkedaS.OkabeK.et al (2020). Mitochondria-dependent ferroptosis plays a pivotal role in doxorubicin cardiotoxicity. JCI Insight5, 132747. 10.1172/jci.insight.132747PubMed Abstract | CrossRef Full Text | Google Scholar
77
TangM.ChenZ.WuD.ChenL. (2018). Ferritinophagy/ferroptosis: Iron-related newcomers in human diseases. J. Cell. Physiol.233, 9179–9190. 10.1002/jcp.26954PubMed Abstract | CrossRef Full Text | Google Scholar
78
TianY.LuJ.HaoX.LiH.ZhangG.LiuX.et al (2020). FTH1 inhibits ferroptosis through ferritinophagy in the 6-OHDA model of Parkinson's disease. Neurotherapeutics17, 1796–1812. 10.1007/s13311-020-00929-zPubMed Abstract | CrossRef Full Text | Google Scholar
79
UrsiniF.MaiorinoM. (2020). Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic. Biol. Med.152, 175–185. 10.1016/j.freeradbiomed.2020.02.027PubMed Abstract | CrossRef Full Text | Google Scholar
80
Van der RietF. D.SayedA. R.BarnardB. J.van TonderE. M.CrouseW. J. (1985). Arthropod-borne virus zoonosis surveillance in the cape province: 1. Prospective serological investigations for virus activity in the beaufort west and middelburg districts during 1981. J. S. Afr. Vet. Assoc.56, 25–29. PubMed Abstract | Google Scholar
81
WangC.SymingtonJ. W.MysorekarI. U. (2012). ATG16L1 and pathogenesis of urinary tract infections. Autophagy8, 1693–1694. 10.4161/auto.21600PubMed Abstract | CrossRef Full Text | Google Scholar
82
WangY. Q.ChangS. Y.WuQ.GouY. J.JiaL.CuiY. M.et al (2016). The protective role of mitochondrial ferritin on erastin-induced ferroptosis. Front. Aging Neurosci.8, 308. 10.3389/fnagi.2016.00308PubMed Abstract | CrossRef Full Text | Google Scholar
83
WangY.ChenQ.ShiC.JiaoF.GongZ. (2019). Mechanism of glycyrrhizin on ferroptosis during acute liver failure by inhibiting oxidative stress. Mol. Med. Rep.20, 4081–4090. 10.3892/mmr.2019.10660PubMed Abstract | CrossRef Full Text | Google Scholar
84
WangH.LiuC.ZhaoY.GaoG. (2020). Mitochondria regulation in ferroptosis. Eur. J. Cell Biol.99, 151058. 10.1016/j.ejcb.2019.151058PubMed Abstract | CrossRef Full Text | Google Scholar
85
WatsonJ. (2013). Oxidants, antioxidants and the current incurability of metastatic cancers. Open Biol.3, 120144. 10.1098/rsob.120144PubMed Abstract | CrossRef Full Text | Google Scholar
86
WuZ.GengY.LuX.ShiY.WuG.ZhangM.et al (2019). Chaperone-mediated autophagy is involved in the execution of ferroptosis. Proc. Natl. Acad. Sci. U. S. A.116, 2996–3005. 10.1073/pnas.1819728116PubMed Abstract | CrossRef Full Text | Google Scholar
87
XuS. (2019). Iron and atherosclerosis: The link revisited. Trends Mol. Med.25, 659–661. 10.1016/j.molmed.2019.05.012PubMed Abstract | CrossRef Full Text | Google Scholar
88
YamadaN.KarasawaT.WakiyaT.SadatomoA.ItoH.KamataR.et al (2020). Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: Potential role of ferroptosis. Am. J. Transpl.20, 1606–1618. 10.1111/ajt.15773PubMed Abstract | CrossRef Full Text | Google Scholar
89
YangM.ChenP.LiuJ.ZhuS.KroemerG.KlionskyD. J.et al (2019). Clockophagy is a novel selective autophagy process favoring ferroptosis. Sci. Adv.5, eaaw2238. 10.1126/sciadv.aaw2238PubMed Abstract | CrossRef Full Text | Google Scholar
90
YangH.LuoF.WeiY.JiaoY.QianJ.ChenS.et al (2021). TGR5 protects against cholestatic liver disease via suppressing the NF-κB pathway and activating the Nrf2/HO-1 pathway. Ann. Transl. Med.9, 1158. 10.21037/atm-21-2631PubMed Abstract | CrossRef Full Text | Google Scholar
91
ZhangY.ShiJ.LiuX.FengL.GongZ.KoppulaP.et al (2018). BAP1 links metabolic regulation of ferroptosis to tumour suppression. Nat. Cell Biol.20, 1181–1192. 10.1038/s41556-018-0178-0PubMed Abstract | CrossRef Full Text | Google Scholar
92
ZhangW.SunY.BaiL.ZhiL.YangY.ZhaoQ.et al (2021). RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. J. Clin. Invest.131, e152067. 10.1172/jci152067PubMed Abstract | CrossRef Full Text | Google Scholar
93
ZhangY.KongY.MaY.NiS.WikerholmenT.XiK.et al (2021). Loss of COPZ1 induces NCOA4 mediated autophagy and ferroptosis in glioblastoma cell lines. Oncogene40, 1425–1439. 10.1038/s41388-020-01622-3PubMed Abstract | CrossRef Full Text | Google Scholar
94
ZhouY.QueK. T.ZhangZ.YiZ. J.ZhaoP. X.YouY.et al (2018). Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl-p53 pathway. Cancer Med.7, 4012–4022. 10.1002/cam4.1670PubMed Abstract | CrossRef Full Text | Google Scholar
95
ZhuS.ZhangQ.SunX.ZehH. J.3rdLotzeM. T.KangR.et al (2017). HSPA5 regulates ferroptotic cell death in cancer cells. Cancer Res.77, 2064–2077. 10.1158/0008-5472.Can-16-1979PubMed Abstract | CrossRef Full Text | Google Scholar
96
ZhuY.XianX.WangZ.BiY.ChenQ.HanX.et al (2018). Research progress on the relationship between atherosclerosis and inflammation. Biomolecules8, E80. 10.3390/biom8030080PubMed Abstract | CrossRef Full Text | Google Scholar
97
ZuccaF. A.Segura-AguilarJ.FerrariE.MuñozP.ParisI.SulzerD.et al (2017). Interactions of iron, dopamine and neuromelanin pathways in brain aging and Parkinson's disease. Prog. Neurobiol.155, 96–119. 10.1016/j.pneurobio.2015.09.012PubMed Abstract | CrossRef Full Text | Google Scholar
Summary
Keywords
ferroptosis, ferritinophagy, iron homeostasis, NCOA4, heme degradation
Citation
Liu M-Z, Kong N, Zhang G-Y, Xu Q, Xu Y, Ke P and Liu C (2022) The critical role of ferritinophagy in human disease. Front. Pharmacol. 13:933732. doi: 10.3389/fphar.2022.933732
Received
10 May 2022
Accepted
01 August 2022
Published
08 September 2022
Volume
13 - 2022
Edited by
Olumayokun Olajide, University of Huddersfield, United Kingdom
Reviewed by
Andrei Adrian Tica, University of Medicine and Pharmacy of Craiova, Romania
Sabzali Javadov, University of Puerto Rico, Puerto Rico
Updates
Copyright
© 2022 Liu, Kong, Zhang, Xu, Xu, Ke and Liu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ping Ke, keping1989@126.com; Chong Liu, wanlc2004@aliyun.com
† These authors have contributed equally to this work
This article was submitted to Inflammation Pharmacology, a section of the journal Frontiers in Pharmacology.
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.